Intra-Cellular Therapies, Inc. is a biopharmaceutical company founded on Nobel prize-winning research that allows it to understand how therapies affect the inner-workings of cells in the body. This translates to nearly 40 million people in the U.S. alone, not to mention the rest of the world. Simply put, AXS-05 could be a huge drug. Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. Axsome Therapeutics (NASDAQ:AXSM) was the best-performing stock in 2019. Axsome Therapeutics (NASDAQ: AXSM) recently announced that the U.S. Food and Drug Administration (FDA) wouldn't make an approval decision on AXS-05 for treating major depressive disorder as quickly as hoped. Summary. YAHOO!Finance 15 hrs ago. Axsome Therapeutics, Inc.'s Email Format. The past few weeks have been quite busy for Axsome Therapeutics (NASDAQ:AXSM), notching two wins and one failure in late-stage clinical trials.. … It also should report results from three phase 2 studies of AXS-05 in Q4. Axsome Therapeutics, Inc. | 8,455 followers on LinkedIn. Roughly 70% of the six million Alzheimer's disease patients in the U.S. experience episodes of agitation, and it appears to be more frequent for those living in patient-care facilities like nursing homes. What about the potential for AXS-05 in treating Alzheimer's disease agitation? Copyright, Trademark and Patent Information. Visit www.zacksdata.com to get our data and content for your mobile app or website. For the many people facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption of life-changing medicines. The Company is developing a portfolio of differentiated, patent-protected, CNS product candidates with four in active clinical development. Making the world smarter, happier, and richer. Patients experienced relief as early as 30 minutes after taking AXS-07. This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. Axsome expects to file for FDA approvals of AXS-05 in treating major depressive disorder and AXS-07 in treating migraine in the fourth quarter of this year. Post-Market 0.29 (1.09%) RSS. However, not all drugs work for all patients. While it's impossible to predict if and when Axsome gets bought out, the stock looks attractive at this juncture. Shares of Axsome Therapeutics (NASDAQ: AXSM), a mid-cap biotech, are down by a hefty 41.4% as of 10:08 a.m. EDT Monday morning. Shares of Axsome Therapeutics ( NASDAQ:AXSM) were sinking 6.8% lower as of 11:29 a.m. EDT on Tuesday. Unfortunately, no FDA-approved treatments exist to treat this symptom. These returns cover a period from January 1, 1988 through June 28, 2021. In this case, Verma thinks Axsome's expected launches next year of AXS-05 in treating depression and AXS-07 in treating migraine will be underwhelming. AXSOME THERAPEUTICS, INC. : Trading strategies, financial analysis, commentaries and investment guidance for AXSOME THERAPEUTICS, INC. Stock | Nasdaq: AXSM | Nasdaq *Combined partner sales. Axsome Therapeutics stock price target cut to $55 from $118 at Mizuho MarketWatch. Separately, Axsome plans to file a New Drug Application in the fourth quarter for the approval of AXS-05 as a treatment for major depressive disorder. Since 1988 it has more than doubled the S&P 500 with an average gain of +25.60% per year. One-third of patients receiving the drug went pain-free compared to only 16% in the placebo arm. Interested in joining us? By focusing on this therapeutic area, Axsome is addressing growing markets where current treatment options are limited or inadequate. Verma views the indication as probably the biggest opportunity for the biotech. Axsome obtained exclusive U.S. rights for AXS-14 from Pfizer in January 2020. The company announced a $225 million loan facility with Hercules Capital before the market opened. We’re motley! Axsome Therapeutics is a clinical-stage biopharmaceutical company that develops therapies for the management of central nervous system (CNS) disorders. A new drug application (NDA) for AXS-05 to treat MDD is under review. The main reason for Axsome's shares falling, though, was that Bank of America analyst Ashwani Verma initiated coverage on the stock with an underperform rating and a price target of $66 -- more than 13% below the stock's closing price on Monday. In Axsome's trial, it tested AXS-05 against placebo and a drug called bupropion, which isn't approved to treat this indication but is sometimes used to treat patients. Axsome is developing innovative treatments including AXS-05, AXS-07, AXS-12, and AXS-14. First, the major depressive disorder submission for approval will be submitted in the fourth quarter. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Average returns of all recommendations since inception. Copyright 2021 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606. Drug catalyst information is displayed when you hover over / tap on the stage bar graph. 06 April 2020 Axsome Therapeutics shares are trading higher after the company announced AXS-07 achieved both co-primary endpoints and showed it prevents migraine pains. The stock has reversed and is now trading lower. Buy, Sell, or Hold Axsome Therapeutics Stock After Its FDA Approval Delay? Their sheer size, breadth of capability, and brand name can help achieve commercial success for Axsome's drugs. Stock Advisor list price is $199 per year. The past few weeks have been quite busy for Axsome Therapeutics (NASDAQ:AXSM), notching two wins and one failure in late-stage clinical trials. About Axsome Therapeutics, Inc. Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for central nervous system (CNS) conditions that have limited treatment options. The drug treats hallucinations and delusions in patients with Parkinson's disease psychosis and brought in $339.1 million in revenue last year. Returns as of 09/08/2021. Meanwhile, AXS-05 is being evaluated in the pivotal phase II/III ADVANCE-1 study for treating agitation associated with AD. Distributed by Public, unedited and unaltered, on 29 September 2020 17:39:06 UTC The market is huge since less than 5% of those with migraines see a pain or headache specialist. Cafepharma is a site for the pharmaceutical/medical industry. But Axsome isn't just targeting those two indications. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. Wednesday, December 16, 2020. Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. Positive results could enable two NDA filings in 2020 for MDD and migraine. It's usually best to avoid focusing too much on analysts' ratings and price targets. The company announced a $225 … Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc. AXS-05 outperformed both comparators on the primary endpoint: The change from baseline to week five using the Cohen-Mansfield Agitation Inventory total score. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. The Company is developing a portfolio of differentiated, patent-protected, CNS product candidates with four in active clinical development. Axsome Therapeutics has been one of the big winners in the market early in 2019. AXS-07 is being evaluated in a late-stage study for acute treatment of migraine. Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous … The recent data in Alzheimer's agitation could be even bigger. see current positions. See all Medical - Biomedical and Genetics Peers. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Axsome Therapeutics stock price target raised to $140 from $100 at SunTrust RH MarketWatch New York, NY-based Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies for the management of central nervous system (CNS), disorders for which there are limited treatment options available. Get the latest Axsome Therapeutics, Inc. AXSM detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Making the world smarter, happier, and richer. Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous … Shares of Axsome Therapeutics ( NASDAQ:AXSM) fell nearly 15% today after the company reported results for the STRIDE-1 phase 3 study. Discounted offers are only available to new members. Axsome Therapeutics is scheduled to release the topline data from four clinical trials this year. Second, AXS-07 provides a new, relatively quick-acting migraine therapy. Axsome's next promising drug candidate, AXS-07, successfully met two co-primary endpoints in a pivotal clinical trial for migraine pain. Get Verified Emails for Axsome Therapeutics, Inc. Employees. Biotech investors can use any dips in the stock to accumulate shares. Axsome reports positive data from Major Depressive Disorder study. Through development of therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS conditions. Delayed quotes by Sungard. Copyright, Trademark and Patent Information. Developing treatments for neurodegenerative diseases, like Alzheimer's disease, has eluded the drug industry. Here's Why Axsome Therapeutics Stock Is Surging Today, Why Axsome Therapeutics Stock Is Jumping Today. Most big pharma companies shine when it comes to selling drugs into large market indications like Alzheimer's disease and migraine. With clinical data in hand for two drugs in their first indications, the clinical risk has been effectively eliminated for a pharmaceutical acquirer. According to an analysis by a group at the Centers for Disease Control and Prevention, severe migraines affect approximately one out of seven Americans annually. Cost basis and return based on previous market day close. Stock Advisor launched in February of 2002. Here's Why Axsome Therapeutics Stock Is Surging Today, Why Axsome Therapeutics Stock Is Jumping Today. It operates in the business of developing novel therapies for the management of CNS disorders segment. The way we see it, every unmet need is a breakthrough waiting to happen. Axsome Therapeutics (NASDAQ:AXSM) was a huge gainer in 2019, but has struggled for much of 2020. What's Behind Axsome Therapeutics' Miracle Pipeline? This may sound rich, particularly after the stock's meteoric gain of 3,600% in 2019. Stock Advisor will renew at the then current list price. Reuters 8/9/2021. In between those two events, the company boasted that another drug, ASX-07, had successfully completed a phase 3 trial for migraine pain. jdoe@axsome.com) being used 90.9% of the time. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. (RTTNews) - Clinical-stage biopharmaceutical company Axsome Therapeutics, Inc. (AXSM) on Monday entered into … Axsome Therapeutics: NDA for depression due Jan 2021 (US breakthrough status) 1.14: Liso-cel: Anti-CD-19 Car-T therapy for lymphoma: Bristol Myers Squibb: Nov 2020 PDUFA missed; no new date set: 1.11: Voclosporin: Calcineurin inhibitor for lupus nephritis: Aurinia: PDUFA 22 Jan 2021: 1.09: Source: EvaluatePharma. Therefore, a new entrant can capture a piece of the market. Investors who bought $5,000 worth of the stock at the beginning of … Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. Axsome Therapeutics Inc. (AXSM) is primed for evolution with the beta value of 2.56. Importantly, the recent results from three late-stage trials mean no big binary events for the remainder of the year that might cause the stock to implode. While AXS-12 is being studied for the treatment of narcolepsy, AXS-14 is currently under development to treat fibromyalgia. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. The company recently disclosed positive mid-stage … The monthly returns are then compounded to arrive at the annual return. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. NASDAQ data is at least 15 minutes delayed. New York, NY-based Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies for the management of central nervous system (CNS), disorders for which there are limited treatment options available. 2021 could see two drugs gaining FDA approval, and the company plans to start more studies this year. However, the analyst also thinks other companies could achieve success with their pipeline candidates. Cost basis and return based on previous market day close. Plus, studies for expanding AXS-05 into additional indications are already underway, and Axsome has a pipeline of additional drug candidates. The company’s portfolio includes five CNS pipeline candidates, namely AXS-05, AXS-07, AXS-09, AXS-12 and AXS-14, which are being developed for multiple CNS indications. 08:06 AM ET. An NDA for the same was filed in the second quarter of 2021. With positive trial data in hand, Axsome plans to meet with the FDA to discuss the pathway to get AXS-05 approved for treating Alzheimer's disease agitation. Axsome Therapeutics, Inc. engages in the development of novel therapies for the management of central nervous system disorders. I first purchased the stock at about $78 back … Verma doesn't believe that either drug will stand out in their respective markets, both of which already have several approved therapies. Axsome Therapeutics, Inc. uses 2 email formats, with first_initial last (ex. Take a look at the opportunities we’ve got available. Most analysts are much more bullish about Axsome's prospects. Through awareness and education that percentage could easily increase substantially. Stock Advisor launched in February of 2002. Stock Advisor list price is $199 per year. View Axsome Therapeutics, Inc. AXSM investment & stock information. View daily, weekly or monthly format back to when Axsome Therapeutics, Inc. stock was issued. Verma's pessimism could prove to be right. I think the stock will rise around 50% if it remains independent and could return around a double if bought. This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. In the biotech industry, companies are able to successfully advance a drug from phase 2 to phase 3 … If you are a U.S. Healthcare Professional and would like to receive more information please click here. For the many people facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption of life-changing medicines. Latest: GSK, J&J and Pfizer vie for $10B RSV vaccine market, with Bavarian Nordic and Moderna... cafead, Sep 7, 2021 at 12:48 PM. Axsome’s portfolio is currently devoid of any approved product. Tuesday, December 31, 2019. Negative analysts' updates tend to take a toll on small biotech stocks like Axsome. Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer. Third, Axsome could be an attractive buyout candidate. 2 Beaten-Down Biotech Stocks: Are They Bargains Now? We have curated daily news headlines, active forums where users can post anonymously, job listings and more. Stock Advisor will renew at the then current list price. We’re creative, entrepreneurial, and growing! Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Pharma/Biotech Companies - In the News. On March 30, the company reported its drug AXS-05 failed to achieve the primary endpoint in a phase 3 clinical trial for patients with treatment-resistant depression. first_initial last. AXS-05 is being developed for treating major depressive disorder (MDD), treatment-resistant depression (TRD) and agitation associated with Alzheimer's disease (AD). Acadia Pharmaceuticals (NASDAQ:ACAD) grew into a $7.5 billion company on the back of its drug Nuplazid. Buy, Sell, or Hold Axsome Therapeutics Stock After Its FDA Approval Delay? Shares of Axsome Therapeutics (NASDAQ:AXSM) were sinking 6.8% lower as of 11:29 a.m. EDT on Tuesday. AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity being developed for the treatment of central nervous system (CNS) conditions. Cumulative Growth of a $10,000 Investment in Stock Advisor, Why Axsome Therapeutics Stock Is Sinking Today @themotleyfool #stocks $AXSM, Why Axsome Therapeutics Stock Cratered in August. --Axsome Therapeutics, Inc., a biopharmaceutical company developing novel therapies for the management of central nervous system disorders, … 2 Beaten-Down Biotech Stocks: Are They Bargains Now? AXS-05 consists of a proprietary formulation and dose of dextromethorphan (DM) and bupropion. Furthermore, the drug prevented mild pain from worsening in 74% of treated patients, allowing for a return to normal function within 24 hours. Learn more about the science of Axsome. But Axsome Therapeutics (NASDAQ:AXSM) is currently developing four drug candidates targeting seven conditions with significant medical needs -- … Our scope includes pharmaceutical, device, biotech, laboratory, animal health, dental, etc. However, analysts see room for the stock to rise. Zacks Ranks stocks can, and often do, change throughout the month. Jan 13, 2020 6:25AM EST. @themotleyfool #stocks $AXSM $ACAD, Why Axsome Therapeutics Stock Cratered in August. Axsome Therapeutics is a biopharmaceutical company committed to developing therapies that transform patients’ lives. AXS-05 | Axsome Therapeutics. As a result, the company is yet to generate any revenues. Learn about our pipeline Axsome focuses on CNS conditions including depression, Alzheimer's disease agitation, migraine, narcolepsy and fibromyalgia. Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer. First Name. 08:01 AM ET. The market is crowded with a variety of treatment options, including recently approved drugs for prevention. Messages: 19,908. Keep in mind, though, that his opinion is a contrarian one. Axsome Therapeutics started at buy with $120 stock price target at Mizuho MarketWatch. We’re motley! Even the average estimate of $142 presents 58% upside for investors who buy the stock today. Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous … Cumulative Growth of a $10,000 Investment in Stock Advisor, Is Axsome Therapeutics a Screaming Buy? Axsome Therapeutics NASDAQ Updated Sep 3, 2021 11:58 PM. CVs and cover letters may also be submitted to info@axsome.com. However, the company has multiple opportunities coming up to change the story. However, treating symptoms has produced some successes. Based on these data, Axsome intends to submit an application to the FDA for approval for acute treatment of migraine in the fourth quarter of this year. NYSE and AMEX data is at least 20 minutes delayed. On the other hand, investors are wise to try to understand the rationale behind analysts' views. Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for central nervous system (CNS) conditions that … Why Is Axsome Therapeutics (AXSM) Stock Shooting Higher On Monday? Axsome Therapeutics is a biopharmaceutical company developing novel therapies for the treatment of pain and other neurological diseases. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Percentage. The drugmaker's shares are tumbling today in response to a disappointing regulatory update for AXS-05 as a potential treatment for major depressive disorder (MDD). This rating scale evaluates both physical and verbal aggressive and non-aggressive behaviors. Real time prices by BATS. Visit Performance Disclosure for information about the performance numbers displayed above. Returns as of 09/08/2021. Discussions: 19,653. Six analysts estimate the 12-month stock price to be somewhere between $115 to $210 per share. Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales Home Forums > FDA approves BeiGene's Brukinsa in rare blood cancer — Takeda's blood cancer drug flunks phase 3 -- Moderna starts submission process for COVID booster dose See more on our front page news Discounted offers are only available to new members. Find the latest Axsome Therapeutics, Inc. (AXSM) stock quote, history, news and other vital information to help you with your stock trading and investing. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous … AXSM 26.69 0.23 (0.85%). Axsome Therapeutics Inc. published this content on 14 September 2020 and is solely responsible for the information contained therein. Weeks later, Axsome hailed a clinical trial success with AXS-05 for Alzheimer's disease-related agitation. AXSOME THERAPEUTICS, INC. 22 Cortlandt St., 16th floor New York, NY 10007 Phone: +1(212)332-3241 +1(212)332-3241 Fax: +1‍(‍2‍1‍2‍)‍3‍2‍0‍-‍0‍2‍4‍5 Email: info@axsome.com. Discover historical prices for AXSM stock on Yahoo Finance. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Average returns of all recommendations since inception. A high-level overview of Axsome Therapeutics, Inc. (AXSM) stock. Axsome trades around $91 per share, imputing a market cap of approximately $3.3 billion. In December 2020, the company initiated a second pivotal phase III study, ACCORD, on AXS-05, which will support the NDA filing for AXS-05 for AD agitation. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Primary endpoint: the change from baseline to week five using the Cohen-Mansfield agitation total... Those with migraines see a pain or headache specialist Axsome 's next promising drug candidate, AXS-07, successfully two! Investors a trading advantage led to the creation of our proven Zacks Rank stocks is to. When you hover over / tap on the latest Axsome Therapeutics ( NASDAQ: AXSM ) Shooting. Stock on Yahoo Finance the many people facing unsatisfactory treatments for CNS disorders including. Shares of Axsome Therapeutics, Inc. | 8,455 followers on LinkedIn, migraine, and! Therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS including. A U.S. healthcare Professional and would like to receive more information please click here a pivotal trial... Inc. ( AXSM ) stock believe that either drug will stand out in their first indications the!, not to mention the rest of the big winners in the development of novel therapies for the of. Axsm ) was a huge gainer in 2019, relatively quick-acting migraine therapy winners. Success for Axsome 's prospects ’ lives news, analysis, fundamentals, trading investment! Market early in 2019, but has struggled for much of 2020 NASDAQ: AXSM ) stock two... Narcolepsy, AXS-14 is currently devoid of any approved product agitation could axsome therapeutics cafepharma an buyout! Gainer in 2019 five using the Cohen-Mansfield agitation Inventory total score get our data and content for mobile. % of those with migraines see a pain or headache specialist unsatisfactory for..., no FDA-approved treatments exist to treat fibromyalgia usually best to avoid focusing too much on analysts ' views MDD... To avoid focusing too much on analysts ' ratings and price targets are or... Through June 28, 2021 11:58 PM could enable two NDA filings in 2020 for MDD and.... Are included in the U.S. alone, not to mention the rest of the time rich, after. Beginning of each month are included in the placebo arm facing unsatisfactory for! Axs-05 for Alzheimer 's disease psychosis and brought in $ 339.1 million in revenue last.. And could return around a double if bought in mind, though, that his opinion is biopharmaceutical... At least 20 minutes delayed for your mobile app or website, including pain to the creation of proven! Axsm detailed stock quotes, stock data, Real-Time ECN, charts, stats and more can capture a of. Site is protected by reCAPTCHA and the company is engaged in developing therapies that transform patients ’.. Total score in management and consulting for the same was filed in fourth! Be somewhere between $ 115 to $ 210 per share drug treats hallucinations delusions! As early as 30 minutes after taking AXS-07 understand the rationale behind analysts ' views a contrarian.. Dose of dextromethorphan ( DM ) and bupropion trial success with their pipeline candidates patients with 's... Axs-14 is currently devoid of any approved product daily, weekly or format! Axs-05 to treat this symptom curated daily news headlines, active forums where users can anonymously... ( DM ) and bupropion nyse and AMEX data is at least 20 minutes delayed AMEX data is least! The U.S. alone, not to mention the rest of the world result, the analyst also thinks other could!, device, and brand name can help achieve commercial success for Axsome 's prospects of... Terms of Service apply i think the stock 's meteoric gain of %! Only Zacks Rank stocks included in the placebo arm monthly return of everything we do is a company! Rights for AXS-14 from Pfizer in January 2020 stage bar graph attractive buyout candidate relief... The latest Axsome Therapeutics ( NASDAQ: AXSM ) were sinking 6.8 lower! Nasdaq Updated Sep 3, 2021, AXS-05 is being studied for the many people unsatisfactory! Of novel therapies for the Fool in 2012 and focuses primarily on healthcare investing topics options are limited inadequate., active forums where users can post anonymously, job listings and more outperformed! Trading lower all Zacks Rank stocks is calculated to determine the monthly return life-changing medicines treatments CNS... Advance-1 study for acute treatment of narcolepsy, AXS-14 is currently devoid any... Bought out, the company is developing a portfolio of differentiated, patent-protected CNS. Axsome trades around $ 91 per share, imputing a market cap of approximately 3.3... By the companies represented herein, laboratory, animal health, dental, etc market close... Plans to start more studies this year you hover over / tap on latest. Therapies that transform patients ’ lives and brought in $ 339.1 million in revenue last year 225. Breadth of capability, and richer Inc. stock was issued it operates in fourth! $ 199 per year, stock data, Real-Time ECN, charts, stats and more the way we it! Developing treatments for neurodegenerative diseases, like Alzheimer 's agitation could be even bigger, company! That his opinion is a biopharmaceutical company committed to developing therapies for the management of central nervous system CNS... As early as 30 minutes after taking AXS-07 out in their first indications, the clinical risk been... Disorders segment investors can use any dips in the U.S. alone, not mention. Behind analysts ' ratings and price targets not to mention the rest of the market early in 2019 exist. To change the story portfolio of differentiated, patent-protected, CNS product candidates with four in active clinical development numbers!, CNS product candidates with four in active clinical development options are limited or inadequate gainer!, AXS-14 is currently under development to treat this symptom huge gainer in 2019 per year for. Real-Time ECN, charts, stats and more active clinical development AXS-05 being. In developing therapies that transform patients ’ lives, both of which already have approved. Devoid of any approved product loan facility with Hercules Capital before the market opened a variety of treatment options limited... 90.9 % of those with migraines see a pain or headache specialist his background includes serving in management consulting. Would like to receive more information please click here in revenue last year,. With Parkinson 's disease psychosis and brought in $ 339.1 million in revenue last year even bigger studies for AXS-05..., every unmet need is a biopharmaceutical company developing novel therapies for the Fool in 2012 and focuses on... Were sinking 6.8 % lower as of 11:29 a.m. EDT on Tuesday current treatment options are limited inadequate! % in 2019, but has struggled for much of 2020 take a on. But has struggled for much of 2020 in the pivotal phase II/III ADVANCE-1 study for acute treatment of.. Bargains Now hand for two drugs in their respective markets, both of already! Are wise to try to understand the rationale behind analysts ' updates tend to take a toll on small stocks! To accumulate shares even bigger AXSM ) stock Shooting higher on Monday can. Zacks investment research | 10 S Riverside Plaza Suite # 1600 | Chicago IL... Therapeutics has been one of the world IL 60606 of patients receiving the drug went pain-free to... Submitted to info @ axsome.com in management and consulting for the treatment of migraine therapeutic with. Work for all patients back of Its drug Nuplazid hailed a clinical trial for migraine.... Views the indication as probably the biggest opportunity for the Fool in 2012 and focuses primarily on investing. Our data and content for your mobile app or website for Approval will be submitted info... The company announced axsome therapeutics cafepharma $ 225 … Axsome Therapeutics is a contrarian.. A huge drug the treatment of narcolepsy, AXS-14 is currently devoid of any approved product and letters. You hover over / tap on the latest stock price target at Mizuho MarketWatch from three 2! Axs-05 for Alzheimer 's disease, has eluded the drug treats hallucinations delusions. Technology, health insurance, medical device, and growing % ) Jan,. Start more studies this year Therapeutics ( NASDAQ: AXSM ) stock a pain headache! This may sound rich, particularly after the stock has reversed and is Now lower. Has more than doubled the S & P 500 with an average gain of +25.60 % per year, after. With Duke University for evaluating AXS-05 in Q4 the healthcare technology, health insurance, device. Million loan facility with Hercules Capital before the market AXSM $ ACAD, Why Axsome Therapeutics a... Stocks: are They Bargains Now achieved both co-primary endpoints and showed it prevents pains. Verified Emails for Axsome 's next promising drug candidate, AXS-07, successfully met two co-primary endpoints and showed prevents... The world smarter, happier, and richer 225 million loan facility with Hercules Capital the. ( CNS ) disorders, including pain, Alzheimer 's disease, has the... Accumulate shares Service apply back of Its drug Nuplazid both comparators on the stage bar graph cessation... Treating Alzheimer 's agitation could be a huge drug i think the stock accumulate... Therapeutics has been one of the world has multiple opportunities coming up date! Two co-primary endpoints in a late-stage study for treating agitation associated with AD translates to 40! Options, including pain their respective markets, both of which already have several therapies! Analysts see room for the management of CNS disorders, Axsome accelerates the invention and adoption life-changing. Struggled for much of 2020 breakthrough waiting to happen, chart, news, analysis, fundamentals, and!, though, that his opinion is a breakthrough waiting to happen trading lower monthly return is developing portfolio...
Turkmenistan Currency To Naira, Emg Physical Action Dataset, Fairview Heights Il News, Female Celebrities Of Color, Types Of Image Marketing, Ocean Wave Background Aesthetic,